These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28096076)

  • 1. A landscape of synthetic viable interactions in cancer.
    Gu Y; Wang R; Han Y; Zhou W; Zhao Z; Chen T; Zhang Y; Peng F; Liang H; Qi L; Zhao W; Yang D; Guo Z
    Brief Bioinform; 2018 Jul; 19(4):644-655. PubMed ID: 28096076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Link synthetic lethality to drug sensitivity of cancer cells.
    Wang R; Han Y; Zhao Z; Yang F; Chen T; Zhou W; Wang X; Qi L; Zhao W; Guo Z; Gu Y
    Brief Bioinform; 2019 Jul; 20(4):1295-1307. PubMed ID: 29300844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.
    Covell DG
    PLoS One; 2015; 10(7):e0127433. PubMed ID: 26132924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.
    Wang L; Li X; Zhang L; Gao Q
    BMC Cancer; 2017 Aug; 17(1):513. PubMed ID: 28768489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies.
    Jiang P; Lee W; Li X; Johnson C; Liu JS; Brown M; Aster JC; Liu XS
    Cell Syst; 2018 Mar; 6(3):343-354.e5. PubMed ID: 29428415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy.
    Sahu AD; S Lee J; Wang Z; Zhang G; Iglesias-Bartolome R; Tian T; Wei Z; Miao B; Nair NU; Ponomarova O; Friedman AA; Amzallag A; Moll T; Kasumova G; Greninger P; Egan RK; Damon LJ; Frederick DT; Jerby-Arnon L; Wagner A; Cheng K; Park SG; Robinson W; Gardner K; Boland G; Hannenhalli S; Herlyn M; Benes C; Flaherty K; Luo J; Gutkind JS; Ruppin E
    Mol Syst Biol; 2019 Mar; 15(3):e8323. PubMed ID: 30858180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.
    Srihari S; Singla J; Wong L; Ragan MA
    Biol Direct; 2015 Oct; 10():57. PubMed ID: 26427375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Interaction-Based Biomarkers Identification for Drug Resistance and Sensitivity in Cancer Cells.
    Han Y; Wang C; Dong Q; Chen T; Yang F; Liu Y; Chen B; Zhao Z; Qi L; Zhao W; Liang H; Guo Z; Gu Y
    Mol Ther Nucleic Acids; 2019 Sep; 17():688-700. PubMed ID: 31400611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies.
    Pozdeyev N; Yoo M; Mackie R; Schweppe RE; Tan AC; Haugen BR
    Oncotarget; 2016 Aug; 7(32):51619-51625. PubMed ID: 27322211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs.
    Wappett M; Dulak A; Yang ZR; Al-Watban A; Bradford JR; Dry JR
    BMC Genomics; 2016 Jan; 17():65. PubMed ID: 26781748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutations, expression and interaction networks in human cancers.
    Wang X; Sun Q
    Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potential synthetic lethal genes to p53 using a computational biology approach.
    Wang X; Simon R
    BMC Med Genomics; 2013 Sep; 6():30. PubMed ID: 24025726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.
    Hansen SN; Ehlers NS; Zhu S; Thomsen MB; Nielsen RL; Liu D; Wang G; Hou Y; Zhang X; Xu X; Bolund L; Yang H; Wang J; Moreira J; Ditzel HJ; Brünner N; Schrohl AS; Stenvang J; Gupta R
    BMC Genomics; 2016 Jun; 17():442. PubMed ID: 27277198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
    Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
    Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
    Glinsky GV
    Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles.
    Li X; Xu Y; Cui H; Huang T; Wang D; Lian B; Li W; Qin G; Chen L; Xie L
    Artif Intell Med; 2017 Nov; 83():35-43. PubMed ID: 28583437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.
    Hintzsche J; Kim J; Yadav V; Amato C; Robinson SE; Seelenfreund E; Shellman Y; Wisell J; Applegate A; McCarter M; Box N; Tentler J; De S; Robinson WA; Tan AC
    J Am Med Inform Assoc; 2016 Jul; 23(4):721-30. PubMed ID: 27026619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance.
    Brubaker D; Difeo A; Chen Y; Pearl T; Zhai K; Bebek G; Chance M; Barnholtz-Sloan J
    Pac Symp Biocomput; 2014; ():125-35. PubMed ID: 24297540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.